Lung cancer is one of the most common malignant tumors, and show an upward trend year by year in China，80% of which is NSCLC. Targeted therapy has become a hot spot in tumor therapy because of its high specificity and less side-effect. Epidermal growth factor receptor (EGFR) plays an important role in the development of various malignant tumors including NSCLC. EGFR overexpression is closely related to tumor growth, angiogenesis, invasion, metastasis and apoptosis inhibition. In addition, EGFR mutation has a significant impact on the response to treatment. So EGFR has become an important molecular target that could monitor biological behavior and predict the therapeutic effect of tumor. At present, a variety of EGFR molecular targeted drugs has been approved by the FDA for clinical applications, such as gefitinib and erlotinib, which have achieved a certain effect. But not all patients with lung cancer could achieve a good effect. And further studies indicated that the treatment effect was closely related with EGFR expression levels and/or mutations in the state. Therefore, the evaluation of EGFR expression and mutation status before the treatment seems to be great significance. The objective of this project is to construct a novel EGFR targeting molecular imaging probe, and reveal EGFR expression and mutation status by noninvasive PET/CT. It is expected to screen for lung cancer patients who would benefit from EGFR targeting therapy, to evaluate the efficacy and to predict the prognosis of lung cancer patients.